Wells Fargo Maintains Overweight on DT Midstream, Raises Price Target to $117
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and real-time intelligence to help traders succeed in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Analyst Views on DTM
About DTM
About the author
DT Midstream to Announce 2025 Financial Results
- Earnings Announcement Schedule: DT Midstream plans to release its fourth quarter and full year 2025 financial results before the market opens on February 19, 2026, which is expected to provide investors with crucial financial data and operational performance insights.
- Conference Call Details: The company has scheduled a conference call for the same day at 9:00 a.m. ET, where investors and media can participate by dialing 888-596-4144 (U.S. and Canada) to further discuss the financial results.
- Webcast Availability: The conference call will be available via a live internet broadcast, allowing the public to listen through the DT Midstream website, ensuring transparency and enhancing engagement with investors.
- Company Background Information: DT Midstream is focused on natural gas pipeline, storage, and gathering systems, serving utilities, power plants, and large industrial customers across the Southern, Northeastern, and Midwestern United States, highlighting its significant role in energy transportation.
B of A Securities Upholds Buy Rating for DT Midstream (DTM)
Analyst Recommendation: B of A Securities has maintained a Buy recommendation for DT Midstream (NYSE:DTM) as of December 11, 2025, with an average one-year price target of $120.17/share, indicating a potential upside of 0.49%.
Revenue and Earnings Projections: DT Midstream's projected annual revenue is $1,049 million, reflecting a decrease of 10.72%, while the projected annual non-GAAP EPS is 4.70.
Fund Sentiment: There are 1,096 funds reporting positions in DT Midstream, with a slight decrease of 2.66% in ownership over the last quarter, and an average portfolio weight of 0.35%, which has increased by 3.70%.
Shareholder Activity: Notable shareholders like IJH and VTSMX have increased their holdings in DT Midstream, while others like Deutsche Bank and Goldman Sachs have significantly reduced their portfolio allocations in the last quarter.
Upcoming Ex-Dividend Dates for DT Midstream, HCA Healthcare, and Thermo Fisher Scientific
Upcoming Ex-Dividend Dates: On 12/15/25, DT Midstream Inc (DTM), HCA Healthcare Inc (HCA), and Thermo Fisher Scientific Inc (TMO) will trade ex-dividend, with respective dividends of $0.82, $0.72, and $0.43 scheduled for payment on 1/15/26 and 12/29/25.
Expected Price Adjustments: Following the ex-dividend date, shares of DTM are expected to open 0.70% lower, HCA by 0.15% lower, and TMO by 0.07% lower, based on their recent stock prices.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 2.79% for DT Midstream Inc, 0.61% for HCA Healthcare Inc, and 0.30% for Thermo Fisher Scientific Inc, reflecting their historical dividend stability.
Current Trading Performance: As of Thursday trading, DT Midstream Inc shares are down about 1.3%, HCA Healthcare Inc shares are down about 4%, while Thermo Fisher Scientific Inc shares have increased by about 1.9%.
In-Depth Analysis of DT Midstream Stock: Insights from Analysts (8 Ratings)
Analyst Ratings Overview: Recent ratings for DT Midstream show a mix of bullish and bearish sentiments, with 4 bullish, 3 indifferent, and 1 somewhat bearish rating among 8 analysts over the past three months.
Price Target Insights: Analysts have set an average 12-month price target of $120.25 for DT Midstream, reflecting a 7.37% increase from the previous average of $112.00, with estimates ranging from $108.00 to $130.00.
Financial Performance Highlights: DT Midstream has demonstrated strong revenue growth of approximately 26.61% and a net margin of 36.62%, although its return on equity (2.45%) and return on assets (1.15%) are below industry benchmarks.
Debt Management Strategy: The company maintains a prudent financial strategy with a below-average debt-to-equity ratio of 0.72, indicating a balanced approach to managing its debt levels.
DT Midstream (DTM) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Citigroup Upholds Buy Rating for DT Midstream (DTM)
Citigroup's Recommendation: Citigroup has maintained a Buy recommendation for DT Midstream (NYSE:DTM) as of October 9, 2025, with an average one-year price target of $111.35/share, indicating a slight upside of 0.16% from its latest closing price.
Fund Sentiment and Ownership Changes: There are 1,120 funds reporting positions in DT Midstream, with a slight decrease in the number of owners but an increase in total shares owned by institutions by 4.25% over the last three months. Notable increases in ownership were reported by Blackstone Group, iShares Core S&P Mid-Cap ETF, and Vanguard Total Stock Market Index Fund.
DT Midstream to Announce 2025 Financial Results
- Earnings Announcement Schedule: DT Midstream plans to release its fourth quarter and full year 2025 financial results before the market opens on February 19, 2026, which is expected to provide investors with crucial financial data and operational performance insights.
- Conference Call Details: The company has scheduled a conference call for the same day at 9:00 a.m. ET, where investors and media can participate by dialing 888-596-4144 (U.S. and Canada) to further discuss the financial results.
- Webcast Availability: The conference call will be available via a live internet broadcast, allowing the public to listen through the DT Midstream website, ensuring transparency and enhancing engagement with investors.
- Company Background Information: DT Midstream is focused on natural gas pipeline, storage, and gathering systems, serving utilities, power plants, and large industrial customers across the Southern, Northeastern, and Midwestern United States, highlighting its significant role in energy transportation.
B of A Securities Upholds Buy Rating for DT Midstream (DTM)
Analyst Recommendation: B of A Securities has maintained a Buy recommendation for DT Midstream (NYSE:DTM) as of December 11, 2025, with an average one-year price target of $120.17/share, indicating a potential upside of 0.49%.
Revenue and Earnings Projections: DT Midstream's projected annual revenue is $1,049 million, reflecting a decrease of 10.72%, while the projected annual non-GAAP EPS is 4.70.
Fund Sentiment: There are 1,096 funds reporting positions in DT Midstream, with a slight decrease of 2.66% in ownership over the last quarter, and an average portfolio weight of 0.35%, which has increased by 3.70%.
Shareholder Activity: Notable shareholders like IJH and VTSMX have increased their holdings in DT Midstream, while others like Deutsche Bank and Goldman Sachs have significantly reduced their portfolio allocations in the last quarter.
Upcoming Ex-Dividend Dates for DT Midstream, HCA Healthcare, and Thermo Fisher Scientific
Upcoming Ex-Dividend Dates: On 12/15/25, DT Midstream Inc (DTM), HCA Healthcare Inc (HCA), and Thermo Fisher Scientific Inc (TMO) will trade ex-dividend, with respective dividends of $0.82, $0.72, and $0.43 scheduled for payment on 1/15/26 and 12/29/25.
Expected Price Adjustments: Following the ex-dividend date, shares of DTM are expected to open 0.70% lower, HCA by 0.15% lower, and TMO by 0.07% lower, based on their recent stock prices.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 2.79% for DT Midstream Inc, 0.61% for HCA Healthcare Inc, and 0.30% for Thermo Fisher Scientific Inc, reflecting their historical dividend stability.
Current Trading Performance: As of Thursday trading, DT Midstream Inc shares are down about 1.3%, HCA Healthcare Inc shares are down about 4%, while Thermo Fisher Scientific Inc shares have increased by about 1.9%.
In-Depth Analysis of DT Midstream Stock: Insights from Analysts (8 Ratings)
Analyst Ratings Overview: Recent ratings for DT Midstream show a mix of bullish and bearish sentiments, with 4 bullish, 3 indifferent, and 1 somewhat bearish rating among 8 analysts over the past three months.
Price Target Insights: Analysts have set an average 12-month price target of $120.25 for DT Midstream, reflecting a 7.37% increase from the previous average of $112.00, with estimates ranging from $108.00 to $130.00.
Financial Performance Highlights: DT Midstream has demonstrated strong revenue growth of approximately 26.61% and a net margin of 36.62%, although its return on equity (2.45%) and return on assets (1.15%) are below industry benchmarks.
Debt Management Strategy: The company maintains a prudent financial strategy with a below-average debt-to-equity ratio of 0.72, indicating a balanced approach to managing its debt levels.
DT Midstream (DTM) Third Quarter 2025 Earnings Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Citigroup Upholds Buy Rating for DT Midstream (DTM)
Citigroup's Recommendation: Citigroup has maintained a Buy recommendation for DT Midstream (NYSE:DTM) as of October 9, 2025, with an average one-year price target of $111.35/share, indicating a slight upside of 0.16% from its latest closing price.
Fund Sentiment and Ownership Changes: There are 1,120 funds reporting positions in DT Midstream, with a slight decrease in the number of owners but an increase in total shares owned by institutions by 4.25% over the last three months. Notable increases in ownership were reported by Blackstone Group, iShares Core S&P Mid-Cap ETF, and Vanguard Total Stock Market Index Fund.
